Jupiter Topco LLC Acquires Shares of 22,883 AtriCure, Inc. $ATRC

Jupiter Topco LLC bought a new position in shares of AtriCure, Inc. (NASDAQ:ATRC) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 22,883 shares of the medical device company’s stock, valued at approximately $640,000.

Several other institutional investors and hedge funds also recently made changes to their positions in ATRC. Vanguard Group Inc. lifted its stake in shares of AtriCure by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 4,903,755 shares of the medical device company’s stock valued at $193,993,000 after purchasing an additional 62,861 shares during the period. BlackRock Inc. acquired a new stake in shares of AtriCure during the second quarter worth $125,198,000. Wellington Management Group LLP increased its holdings in AtriCure by 8.1% in the third quarter. Wellington Management Group LLP now owns 4,292,087 shares of the medical device company’s stock valued at $151,296,000 after purchasing an additional 322,818 shares during the last quarter. First Light Asset Management LLC lifted its stake in AtriCure by 32.0% in the fourth quarter. First Light Asset Management LLC now owns 1,175,445 shares of the medical device company’s stock valued at $46,501,000 after buying an additional 285,083 shares during the period. Finally, Dimensional Fund Advisors LP grew its position in shares of AtriCure by 8.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 997,759 shares of the medical device company’s stock worth $28,466,000 after buying an additional 75,862 shares during the period. Institutional investors own 99.11% of the company’s stock.

AtriCure Stock Performance

NASDAQ ATRC opened at $51.52 on Monday. The firm’s fifty day moving average price is $40.10 and its two-hundred day moving average price is $32.83. The firm has a market capitalization of $2.62 billion, a P/E ratio of 245.35 and a beta of 1.26. The company has a current ratio of 4.22, a quick ratio of 3.19 and a debt-to-equity ratio of 0.14. AtriCure, Inc. has a 1 year low of $25.36 and a 1 year high of $53.50.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings results on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. The business had revenue of $153.60 million for the quarter, compared to analyst estimates of $151.80 million. During the same quarter in the prior year, the business earned ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, research analysts anticipate that AtriCure, Inc. will post 0.29 EPS for the current year.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. Weiss Ratings raised shares of AtriCure from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, August 19th. Citigroup restated a “market outperform” rating on shares of AtriCure in a research report on Tuesday, July 21st. Piper Sandler boosted their target price on AtriCure from $50.00 to $60.00 and gave the company an “overweight” rating in a research note on Thursday, August 27th. Zacks Research lowered AtriCure from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 24th. Finally, Raymond James Financial set a $52.00 target price on AtriCure in a research note on Tuesday, July 21st. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $52.00.

Insider Buying and Selling

In related news, insider Vinayak Doraiswamy sold 6,000 shares of AtriCure stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $38.88, for a total value of $233,280.00. Following the transaction, the insider directly owned 86,511 shares of the company’s stock, valued at $3,363,547.68. This trade represents a 6.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Justin J. Noznesky sold 6,182 shares of AtriCure stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $38.80, for a total value of $239,861.60. Following the completion of the transaction, the insider owned 100,219 shares in the company, valued at approximately $3,888,497.20. The trade was a 5.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 61,379 shares of company stock valued at $2,557,552 in the last ninety days. Insiders own 4.00% of the company’s stock.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.